Revenue
2011
2012
2013
2014
2019
2020
2021
2022
2023
2024
2025
SELLAS Life Sciences Group, Inc. (SLS)
Price$11.49Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2013
2014
2015
2016
2022
2023
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.0M | $7.6M | $1.9M | $0 | — | — | — | — | $9.3M | $2.5M | $0 | $0 | — |
| Gross profit | — | — | $0 | $900,000 | $7.4M | $1.9M | — | — | — | — | — | $7.9M | $2.0M | $0 | $0 | — |
| Gross margin | — | — | — | 90.00% | 97.37% | 100.00% | — | — | — | — | — | 84.94% | 79.09% | — | — | — |
| Research & development | $16.0M | $19.1M | $24.0M | $20.3M | $15.7M | $9.3M | $7.3M | $8.8M | $6.1M | $19.9M | $23.6M | $27.7M | $20.4M | $14.6M | $3.9M | $6.0M |
| Operating expenses | $28.3M | $31.5M | $37.9M | $43.0M | $32.9M | $18.9M | $20.0M | — | — | $31.9M | $34.2M | $43.9M | $28.5M | $21.2M | $12.5M | $16.6M |
| Operating income | −$28.3M | −$31.5M | −$37.9M | −$42.0M | −$25.3M | −$17.0M | −$20.0M | — | −$23.0M | −$16.0M | −$34.2M | −$43.9M | −$28.5M | −$21.2M | −$12.5M | — |
| Operating margin | — | — | — | −4,195.00% | −332.82% | −893.79% | — | — | — | — | — | −471.08% | −1,145.52% | — | — | — |
| EBITDA | −$28.3M | −$31.5M | −$37.9M | −$31.9M | — | — | — | — | — | −$16.0M | −$34.1M | −$43.8M | −$28.2M | −$21.1M | −$12.3M | — |
| EBITDA margin | — | — | — | −3,195.00% | — | — | — | — | — | — | — | −470.16% | −1,134.02% | — | — | — |
| Net income | −$26.9M | −$30.9M | −$37.3M | −$41.3M | −$20.7M | −$16.8M | −$19.3M | −$27.7M | −$23.8M | −$17.7M | −$63.9M | −$36.6M | −$76.7M | −$35.0M | −$11.5M | −$12.0M |
| Net profit margin | — | — | — | −4,130.10% | −272.36% | −881.95% | — | — | — | — | — | −392.81% | −3,083.15% | — | — | — |
| Basic EPSper basic share | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$26,100.00 | -$46,650.00 | -$685,833.33 | -$510,833.33 | -$1,416,666.67 | -$933,333.33 | -$533,333.33 | -$1,116,666.67 |
| Diluted EPSper diluted share | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | -$10.92 | -$157.72 | -$26,100.00 | -$46,650.00 | -$685,833.33 | -$510,833.33 | -$1,416,666.67 | -$933,333.33 | -$533,333.33 | -$1,116,666.67 |
Owners
Reported shareholders
7.46%of listed shares
BlackRock, Inc.15.07M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 7.46%15.07M shares |
STATE STREET CORP | 6.44%13M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.07%8.23M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.42%4.88M shares |
Anson Funds Management LP | 2.23%4.5M shares |
JONES FINANCIAL COMPANIES LLLP | 1.14%2.3M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.07%2.16M shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.02%2.05M shares |
Stergiou Angelos M. | ≈0.87%1.76M shares |
NORTHERN TRUST CORP | 0.80%1.62M shares |
VANGUARD FIDUCIARY TRUST CO | 0.66%1.34M shares |
UBS Group AG | 0.62%1.25M shares |
MORGAN STANLEY | 0.61%1.24M shares |
DAGCO, INC. | 0.61%1.23M shares |
BNP PARIBAS FINANCIAL MARKETS | 0.53%1.07M shares |
BANK OF AMERICA CORP /DE/ | 0.39%787.95K shares |
WELLINGTON MANAGEMENT GROUP LLP | 0.30%597.31K shares |
GOLDMAN SACHS GROUP INC | 0.29%585.04K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.28%565.01K shares |
CICIC DRAGAN | ≈0.28%557.81K shares |
Percentages use 201.92M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 19, 2025Form 4 | Kalin Katherine BachDirector | BuyCommon Stock | 63.4K | $1.59 | $100.8K | 104.4K |
| Jun 12, 2025Form 4 | VAN NOSTRAND ROBERT LDirector | BuyCommon Stock | 10.0K | $1.48 | $14.8K | 20.4K |
| May 30, 2025Form 4 | Wasman JaneDirector | BuyCommon Stock | 20.0K | $1.69 | $33.8K | 30.4K |
| May 22, 2025Form 4 | Kalin Katherine BachDirector | BuyCommon Stock | 20.0K | $1.80 | $36.0K | 41.0K |